Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited

NURPF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.74B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Neuren Pharmaceuticals LimitedNeuren Pharmaceuticals Limited145.30.65%51%6.9-
$1.92

Current Fair Value

86% downside

Overvalued by 86% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.74 Billion
Enterprise Value$1.72 Billion
Annual dividend$0.10
Dividend yield0.65%
Earnings per Share$0.24
Beta1.59
Outstanding Shares126,773,976

Return

Return on Equity50.85%ROE
Return on Assets49.77%
Return on Invested Capital60.01%

Valuation & Multiples

P/E Ratio145.29P/E Ratio
PEG-214.41PEG
Price to Sales6.88Price to Sales
Price to Book Ratio6.88Price to Book Ratio
Enterprise Value to Revenue5.92
Enterprise Value to EBIT8.59
Enterprise Value to Net Income10
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 24, 2026
EPS
$0.03
Est. $0.06
Revenue
$22.94 M
Est. $22.25 M

Next Earnings Call

Expected Date
February 24, 2027
EPS Estimate
$0.25
Consensus analyst estimate
Revenue Estimate
$63.43 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Neuren Pharmaceuticals Limited

9 employees
CEO: Jonathan Charles Pilcher

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patie...